NN
NNFN.F MannKind Corporation
- Market cap
- EUR 1.19B
- P/E
- -
- P/B
- 189.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NNFN.F undervalued?
Graham numberThe Graham number of MannKind Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MannKind Corporation fundamental analysis
No fundamental analysis for MannKind Corporation yet.
MannKind Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation…
Full company profileMannKind Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MannKind Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 175M | 11.7M | 27.9M | 63.0M | 65.1M | 75.4M | 99.8M | 199M | 286M | 349M | 402M |
| Gross Profit | 125M | -5.48M | 7.38M | 35.1M | 40.5M | 36.6M | 42.3M | 136M | 209M | 261M | 308M |
| Operating Income | 65.1M | -94.3M | -81.1M | -46.5M | -24.8M | -53.5M | -68.9M | 10.6M | 68.7M | 46.6M | -8.53M |
| EBITDA | - | -100M | -74.4M | -38.8M | -44.7M | -58.9M | -62.6M | 19.1M | 75.7M | 51.5M | 648K |
| Net Income | 126M | -117M | -87.0M | -51.9M | -57.2M | -80.9M | -87.4M | -11.9M | 27.6M | 5.86M | -78.5M |
| EPS | - | -0.99 | -0.47 | -0.25 | -0.24 | -0.32 | -0.33 | -0.04 | 0.09 | 0.02 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 107M | 84.6M | 108M | 93.7M | 109M | 321M | 295M | 475M | 394M | 792M | 723M |
| Total Liabilities | 291M | 299M | 283M | 284M | 289M | 531M | 546M | 721M | 473M | 843M | 760M |
| Shareholders' Equity | -184M | -215M | -175M | -191M | -180M | -209M | -251M | -246M | -78.8M | -51.0M | -37.3M |
| Cash & Short-term Investments | 22.9M | 43.9M | 71.2M | 29.9M | 67.0M | 124M | 69.8M | 238M | 46.3M | 74.9M | 41.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -78.1M | -64.8M | -37.7M | -88.5M | -28.1M | -61.7M | -80.7M | 34.1M | 42.5M | 18.3M | -77.7M |
| Capital Expenditure | 1.14M | 354K | 354K | 2.57M | 801K | 11.5M | 7.59M | 42.4M | 9.69M | 4.57M | 13.6M |
| Free Cash Flow | - | -64.8M | -38.1M | -91.0M | -32.9M | -73.2M | -88.3M | -8.35M | 32.8M | 13.7M | -91.3M |
| Ratios | |||||||||||
| ROA | 117.4% | -138.7% | -80.8% | -55.4% | -52.7% | -25.2% | -29.6% | -2.5% | 7.0% | 0.7% | -10.9% |
| Net Profit Margin | 71.9% | -999.0% | -312.2% | -82.3% | -87.9% | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% | -19.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MannKind Corporation dividends
MannKind Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Mar 3, 2017.
Who owns MannKind Corporation
- Insiders 1.47%
- Institutions 56.33%
- Public & others 42.21%
- Shares outstanding 322M
- Free float 298M
MannKind Corporation company profile
- Company name
- MannKind Corporation
- Ticker
- NNFN.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 591
- Fiscal year end
- December
- Address
- 1 Casper Street, Danbury, CT, United States, 06810
- Phone
- 818 661 5000
- Website
- mannkindcorp.com
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corporation management
8- Dr. Michael E. Castagna Pharm.D.CEO & Director · born 1976
- Mr. Christopher B. Prentiss M.B.A.Chief Financial Officer · born 1975
- Dr. David B. Thomson J.D., Ph.D.Executive VP, General Counsel & Secretary · born 1967
- Dr. Stuart A. Tross Ph.D.Chief People & Workplace Officer · born 1967
- Mr. Dominic Marasco R.Ph.President of Endocrine Business Unit · born 1972
- Mr. Sanjay Singh M.B.A.Executive Vice President of Technical Operations · born 1966
- Dr. Ajay Ahuja M.B.A., M.D.Executive VP & Chief Medical Officer · born 1970
- Dr. Wassim Fares M.D., M.Sc.Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal